A new study indicates that the antiviral drug oseltamivir can reduce influenza infections and prevent deaths in a cost-saving manner under most pandemic scenarios.
Investigators' analyses of phase II clinical data and information from a previous influenza outbreak revealed that oseltamivir 75 mg relative to no treatment was effective and affordable under all scenarios. Oseltamivir 150 mg relative to 75 mg was not cost effective in low transmissibility scenarios but was cost saving in high transmissibility scenarios.
↧